[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.225.99. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 2, 1953

EVALUATION OF HEPATIC TESTS AND CLINICAL FINDINGS IN PRIMARY HEPATIC CANCER

Author Affiliations

Staten Island, N. Y.

From the Gastrointestinal Division, Department of Medicine, United States Public Health Service Hospital, Staten Island; Senior Resident (Dr. Galluzzi), Deputy Chief of the Medical Service (Dr. Weingarten), consultant in internal medicine (Dr. Regan), and Chief of the Medical Service (Dr. Doerner).

JAMA. 1953;152(1):15-16. doi:10.1001/jama.1953.03690010021004
Abstract

The importance of primary hepatic cancer has been stressed in recent reports in the literature. At the United States Public Health Service Hospital, Staten Island, N. Y., we have had the opportunity to study 19 proved cases of primary hepatic carcinoma, with special emphasis on the detailed analysis of hepatic tests as well as the pertinent clinical features. It is well known that primary hepatic cancer is a rare disease in European and North American populations. In Europe, this entity is seen in 0.13% of all autopsies and comprises 1.1% of all carcinomas, and in America, it is seen in 0.25% of all autopsies and comprises 2.1% of all carcinomas, while in the Orient it is seen in 0.85% of all autopsies and comprises 14.1% of all carcinomas. The incidence of hepatic cancer at this institution is unusually high in comparison to that for Europe and North America. This disease

First Page Preview View Large
First page PDF preview
First page PDF preview
×